Table 5.

Blood markers at baseline and end point in the intervention and usual care groups

nMean (SD)Group mean difference in Δa (95% CI)Pb
BaselineEnd point
Usual careInterventionUsual careIntervention
Insulin, mU/L4210.8 (12.7)10.4 (13.2)11.7 (14.2)8.91 (8.4)−2.3 (−12.5 to 7.8)0.46
IGFBP-3, ng/mL423,052.5 (750.7)3,098.1 (738.2)2,964.7 (796.2)2,875.7 (827.3)−134.6 (−503.9 to 234.6)0.49
IGF-1, ng/mL4277.6 (25.8)74.5 (21.5)79.4 (27.2)78.3 (22.6)1.9 (−6.9 to 10.8)0.72
IGFBP-1, ng/mL4234.5 (24.4)32.6 (25.9)38.4 (26.2)36.4 (26.4)−0.18 (−12.1 to 11.7)0.91
PSA, ng/mL505.02 (10.2)3.32 (6.83)6.24 (13.6)4.55 (8.74)0.01 (−2.2 to 2.2)0.61
Serum testosterone, nmol/L403.19 (6.97)4.12 (8.69)3.85 (8.67)4.50 (8.01)−0.28 (−1.8 to 1.2)0.68
Free androgen index398.52 (19.4)12.4 (24.3)9.44 (21.5)13.5 (22.8)0.22 (−3.3 to 3.8)0.87
Sex hormone–binding globulin, nmol/L4045.1 (13.6)41.6 (13.2)46.8 (14.0)40.8 (11.8)−2.5 (−6.4 to 1.5)0.13

aΔ (delta) from baseline in intervention group minus Δ from baseline in usual care group. A negative score indicates a greater decrease in the intervention group and a positive score a greater increase.

bANCOVA of end point score adjusting for baseline score, effect of group.